Gene · 10112
Papers1,613
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
41 to 60 of 1,613
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| KIF20A drives epithelial cell proliferation and migration in gastric adenocarcinoma, facilitating macrophage M2 polarization and subsequent immune evasion. | Int J Biol Macromol | 2026 | 41713545 | PubTator, text mining | PubMed |
| KIF20A suppresses ferroptosis in HCC through HMOX1/SLC7A11/GPX4 signaling pathway. | Discov Oncol | 2026 | 41701424 | PubTator, text mining | PubMed |
| KIF20A inhibits TRIM21-dependent ubiquitination of DHX9 to boost SOX2 stability, enhancing OSCC stemness and ferroptosis resistance. | Cell Death Dis | 2026 | 41672965 | PubTator, text mining | PubMed |
| Targeting KIF20A: a new frontier in cancer treatment revealed by multi-omics analysis. | Front Immunol | 2026 | 41646843 | PubTator, text mining | PubMed |
| Ferroptosis-related gene signature predicts prognosis and immunotherapy response in hepatocellular carcinoma: A multi-cohort retrospective study. | Medicine (Baltimore) | 2026 | 41578512 | PubTator, text mining | PubMed |
| Integrated Network Analysis Reveals a Directly Regulatory Network of FOXM1 Associated With the Cell Cycle in Lung Adenocarcinoma. | Bioinform Biol Insights | 2026 | 41541229 | PubTator, text mining | PubMed |
| FOXM1 regulates platelet-induced anoikis resistance in pancreatic cancer cells. | Cell Commun Signal | 2026 | 41535944 | PubTator, text mining | PubMed |
| Glycolysis reprogramming predicts poor prognosis and drives therapy resistance via CLN6 in lethal prostate cancer. | Acta Biochim Biophys Sin (Shanghai) | 2026 | 41527450 | PubTator, text mining | PubMed |
| Integrating multiple key molecules in uveal melanoma to uncover metastatic and immune microenvironment-related gene signatures. | Int J Ophthalmol | 2026 | 41523997 | PubTator, text mining | PubMed |
| SYMPK interacts with KIF20A and NUMA1 to coordinate spindle organization and safeguard oocyte meiotic maturation. | J Genet Genomics | 2026 | 41520922 | PubTator, text mining | PubMed |
| Single-cell and machine learning-based analysis of the molecular mechanism of Banxia Xiexin Decoction in the treatment of gastric cancer. | Cytotechnology | 2026 | 41510325 | PubTator, text mining | PubMed |
| A novel prognostic model in ovarian cancer based on the Nectin family and Necl-like molecules related transcriptomics. | SLAS Technol | 2026 | 41391606 | PubTator, text mining | PubMed |
| Hypoxia Triggers ALYREF-Mediated m5C Methylation of KIF20A to Activate KIF20A/BUB1 for Generating Ferroptosis Resistance in Cervical Cancer Cells. | Kaohsiung J Med Sci | 2026 | 40914946 | PubTator, text mining | PubMed |
| Differentially Expressed Genes Associated with the Development of Cervical Cancer. | Int J Mol Sci | 2025 | 41516135 | PubTator, text mining | PubMed |
| Kinesin genes KIF4A, KIF20A and KIF11 as prognostic biomarkers in lung adenocarcinoma by integrative bioinformatic analysis and experimental validation. | Sci Rep | 2025 | 41462522 | PubTator, text mining | PubMed |
| Identification of key candidate genes for ovarian cancer using integrated statistical and machine learning approaches. | Brief Bioinform | 2025 | 41405958 | PubTator, text mining | PubMed |
| Targeting kinesin family member 20A sensitizes stem-like triple-negative breast cancer cells to standard chemotherapy. | J Clin Invest | 2025 | 41392981 | PubTator, text mining | PubMed |
| Epirubicin Induces Cell Cycle Arrest in Multiple Myeloma Cells by Downregulating CDC20 Expression. | Front Biosci (Landmark Ed) | 2025 | 41351409 | PubTator, text mining | PubMed |
| KIF20A as a driver of anti-PD-1 resistance via PD-L1 downregulation in NSCLC: a biomarker validation and tumor microenvironment analysis. | BMC Cancer | 2025 | 41267030 | PubTator, text mining | PubMed |
| Crotonoside exerts anti-colorectal cancer effects by suppressing KIF20A to regulate the cell cycle. | Sci Rep | 2025 | 41266758 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10112/papers?page=3